Physician profile
Gerard Chaaya
NPI 1508270778
$19,651.52
in general payments reported to CMS, 2019-2025
67 companies · $304 in 2025
The $304 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,488 · 2020: $2,033 · 2021: $4,152 · 2022: $6,024 · 2023: $4,863 · 2024: $788 · 2025: $304.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,866 · Consulting Fee: $2,055 · Education: $34.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,865.67 |
| Consulting Fee | $2,055.00 |
| Education | $34.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $4,996.95 | 2020-2025 | Imfinzi, Calquence, Enhertu |
| Celgene Corporation | $1,267.49 | 2019-2024 | Reblozyl, Pomalyst |
| Merck Sharp & Dohme LLC | $1,076.96 | 2019-2025 | Keytruda, Lynparza, Welireg |
| E.R. Squibb & Sons, L.L.C. | $888.43 | 2019-2024 | Opdivo |
| Genentech USA, INC. | $775.08 | 2019-2023 | Lunsumio, Polivy, Venclexta |
| Seagen INC. | $673.02 | 2019-2023 | Padcev, Adcetris, Tukysa |
| Astellas Pharma US INC | $672.22 | 2019-2024 | Xospata, Xtandi |
| Eisai INC. | $640.75 | 2019-2024 | |
| Pfizer INC. | $622.65 | 2019-2024 | |
| Janssen Biotech, INC. | $568.19 | 2019-2024 | Darzalex, Erleada, Imbruvica |
| Amgen INC. | $543.84 | 2019-2023 | Lumakras, Kyprolis |
| Genzyme Corporation | $524.09 | 2019-2024 | |
| Glaxosmithkline, LLC. | $416.59 | 2020-2025 | Jemperli, Shingrix, Zejula |
| Novartis Pharmaceuticals Corporation | $402.30 | 2019-2025 | |
| Incyte Corporation | $348.89 | 2019-2023 | Jakafi |
Show all 67 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerard Chaaya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.